Viking Therapeutics (VKTX) Assets Average (2015 - 2026)

Viking Therapeutics has disclosed Assets Average across 12 years of filings, most recently posting $662.0 million for Q1 2026.

• Assets Average for Q1 2026 came in at $662.0 million, down 25.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $662.0 million (down 25.42% YoY), and the FY2025 annual result was $812.0 million, up 27.2% from the prior year.
• Assets Average came in at $662.0 million for Q1 2026 at Viking Therapeutics, down from $727.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $957.2 million in Q2 2024 to a low of $159.7 million in Q1 2023.
• The 5-year median for Assets Average is $662.0 million (2026), against an average of $549.1 million.
• Across the five-year window, Assets Average surged 318.26% in 2024 and decreased 25.42% in 2026, its largest moves.
• Viking Therapeutics' Assets Average stood at $167.6 million in 2022, then jumped by 124.08% to $375.6 million in 2023, then surged by 145.78% to $923.1 million in 2024, then slipped by 21.18% to $727.6 million in 2025, then retreated by 9.01% to $662.0 million in 2026.
• The last three Assets Average figures came in at $662.0 million (Q1 2026), $727.6 million (Q4 2025), and $783.6 million (Q3 2025), per Business Quant data.